Bristol Myers Squibb ends development of Orum Therapeutics' ORM-6151 after early trial review
Bristol Myers Squibb has stopped work on ORM-6151, a degrader-antibody conjugate from Orum Therapeutics, after reviewing Phase I trial data.
Small molecule 1 article
Low-molecular-weight drug compounds is central to small molecule, a low-molecular-weight chemical drug modality with a defined biotechnology role. Oral drug discovery works together with intracellular target modulation, while enzyme inhibitor design and receptor ligand discovery establish the main biological or analytical context in which the entity is interpreted. For entity matching, neighboring methods and products remain separate from the defined concept small molecule.